[October 20, 2017]

Global Cystic Fibrosis Therapeutics Market (By Major Marketed Products, Pharmacological Class, & Geography) and Pipeline Analysis 2017-2024 - Research and Markets

The "Cystic Fibrosis Therapeutics Market (By Major Marketed Products, Pharmacological Class, & Geography) and Pipeline Analysis - Global Forecast to 2024" report has been added to Research and Markets' offering.

The market for Cystic Fibrosis Therapeutics is anticipated to grow with double digit CAGR during the forecasting period.

The increasing prevalence of cystic fibrosis, rising awareness about cystic fibrosis therapy, strong pipeline candidates, technological advancement and high rate of R&D initiatives are some of the major factors that are driving cystic fibrosis therapeutics market. However, high cost involved in treatment, increase in complexity of disease are restraining the cystic fibrosis therapeutics market.

Key Highlights of the Report

• United States dominates the global market for cystic fibrosis therapeutics.
• The EU5 countries together accounted for over 20% share of the global cystic fibrosis market in 2016.
• In Asian region, the prevalence of Cystic Fibrosis is observed to be very low in countries like China, India and Japan.
• On the basis of pharmacological class, the CFTR modulator captures highest share of the total CF therapeutics market in 2016.
• Cystic Fibrosis patients who have reduced the levels of digestive enzymes due to improper functioning of pancreas, are treated by PERT to replace these enzymes.
• Italy has followed Ireland and other EU countries such as Germany, Austria, Denmarkand Luxembourg in approving Orkambi for patients with CF.
• It's estimated that 1 in every 2,500 babies born in the UK has cystic fibrosis.
• The revenues for Creon increased 22 percent in 2015, driven primarily by continued market growth.
• Zenpep sales surpassed US$ 200 Million mark in 2016.
• Some of the drugs that are under clinical studies are Tezacaftor (VX-661) + ivacaftor, VX-445 + tezacaftor + ivacaftor, VX-659 + tezacaftor + ivacaftor, PTI-428, AZD5634, QR-010 and POL6014 among many others.

• Orkambi (Lumacaftor/Ivacaftor)
• Kalydeco (Ivacaftor)
• Cayston (Inhaled Aztreonam)
• Pulmozyme (Dornase Alfa)
• TOBI/ TOBI Podhaler
• Creon
• Zenpep
• Ventolin
• Bronchitol (Inhaled Mannitol)
• ADEKplusTM
• Ibuprofen

Global Cystic Fibrosis Therapeutics Market - Pharmacological Class

• CFTR Modulators
• Mucolytic Agents
• Pancreatic Enzyme Replacement Products
• Antibiotics
• Other Therapies

Cystic Fibrosis Company Profiles, Approved & Pipeline Product Analysis

• Genentech, Inc. (A Member of the Roche Group)
• Novartis
• Gilead Sciences, Inc.
• Vertex (News - Alert) Pharmaceuticals Incorporated
• AbbVie
• GlaxoSmithKline
• Johnson & Johnson
• Allergan plc
• Pharmaxis Ltd
• Mylan N.V

Key Topics Covered:

1. Executive Summary

2. Global Cystic Fibrosis Therapeutics Market & Forecast (2014 - 2024)

3. Global Cystic Fibrosis Therapeutics Market Share & Forecast

4. Global Cystic Fibrosis Therapeutics Market - Major Marketed Products Sales & Forecast

5. Global Cystic Fibrosis Therapeutics Market - Pharmacological Class Sales & Forecast (2015 - 2021)

6. By Geography - Cystic Fibrosis Therapeutics Market (2014 - 2024)

7. Global Cystic Fibrosis Pipeline Product Analysis - By Company & Phase of Development

8. Cystic Fibrosis Company Profiles, Approved & Pipeline Product Analysis

9. Global Cystic Fibrosis Market - Industry Trends & Developments

10. Global Cystic Fibrosis Market - Growth Drivers

11. Global Cystic Fibrosis Market - Challenges

For more information about this report visit https://www.researchandmarkets.com/research/dfsfp9/cystic_fibrosis

View source version on businesswire.com: http://www.businesswire.com/news/home/20171020005369/en/

[ Back To TMCnet.com's Homepage ]